Development of GE11-Functionalized Liposomes for Doxorubicin and Curcumin Delivery in Breast Cancer Treatment

Juliana Oliveira, Ph.D – Post-doc, Biochemistry, Institute of Biology, University of Campinas; Talita Mendonça, MS – student, Biochemistry, Institute of Biology, University of Campinas (Unicamp); Daniely Paspardelli – undergraduate student, Biochemistry, Institute of Biology, University of Campinas; Eneida de Paula, PhD – Full professor, Biochemistry, Institute of Biology, University of Campinas (Unicamp)

Introduction: Breast cancer is the second most prevalent cancer among women worldwide [1]. Conventional therapies are often non-selective, affecting both tumor and healthy tissues, which highlights the need for improved treatment strategies. Liposomes are promising drug delivery systems, as they enhance drug bioavailability, reduce chemoresistance, and enable synergistic effects of actives. Moreover, liposomes functionalized with GE11 peptide, targeting EGFR-overexpressing tumors, allow selective delivery to cancer cells, potentially improving treatment efficacy while minimizing systemic toxicity [2].